Why this ASX 200 healthcare share is bucking today's market sell-off

Shares in Clinuvel Pharmaceuticals Limited (ASX: CUV) are up over 8% today, bucking the broader market trend.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in Clinuvel Pharmaceuticals Limited (ASX: CUV) are up more than 9% today, bucking the broader market trend. The ASX 200 healthcare company announced today that it plans to launch its drug Scenesse in the US in April, which has given its share price a boost. 

FDA approved 

Scenesse was approved by the FDA in October 2019 for the treatment of rare metabolic disorder erythropoietic protoporphyria (EPP). EPP causes a painful burning sensation of the skin after sun exposure. Scenesse works to increase pain free light exposure. The first US EPP patient will be treated with Scenesse on 15 April. 

Phased implementation 

Distribution in the US is planned to occur in 3 phases. In phase 1, 3 selected hospitals and medical centres will be able to provide treatment to EPP patients. For phase 2, Medicare-Medicaid will need to complete its review of the Scenesse dossier and provide an opinion on coverage of the treatment. The last phase will consist of direct distribution of the drug to a target maximum of 30 centres, which will be trained and accredited by Clinuvel. 

During the first phase commencing on 15 April 2020, patients will be able to receive treatment under Prior Authorisation. Prior Authorisation is a decision by a payer that a healthcare service or prescription drug is medically necessary and is included in the patient's coverage. 

Payment plans 

Clinuvel plans to establish a Co-Payment Savings Program for American EPP patients. Individual applications will need to be made by patients, and terms and conditions will apply to patients on a case by case basis. EPP patients with commercial or private health insurance may be eligible, depending on the terms of each insurance policy. 

"Contrary to our predictions that the drug would be made available during the 4th quarter of this year, our teams have managed to complete the entire process working closely with the Food and Drug Administration," Clinuvel's CEO Dr Philippe Wolgen said in today's announcement. "It is satisfying to be able to serve our patient population facilitating them a freedom to live without inhibition and handicap," he added.

With the outbreak of coronavirus, Clinuvel is monitoring the clinical attendance of EPP patients in the European Union. The outlook, however, remains positive, with meetings scheduled with the Food and Drug Administration to discuss the development of a program using Scenesse to treat vitiligo. 

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »